CHF 40,000 for video consumption with AI, next-gen immunotherapy, and advanced recycling solutions
24.04.2024
OptiVerse, Shape Biopharmaceuticals, and WasteFlow were selected at Venture Kick's second financial and entrepreneurial support stage. Their projects offer an innovative solution capable of summarizing extensive videos into concise video summaries; combine immunobiology, chemistry, and medicine expertise to develop its medicines with state-of-the-art computer-aided drug design; and turn waste into value with vision.
 |
 |
 Optiverse: CTO Raphael Ausilio, CEO Elio Assaf, and COO Mario Assaf
|
|
 Shape Biopharmaceuticals: Co-founder and CEO Dr. Arin Ghasparian
|
|
 WasteFlow: Co-Founders CEO Valentin Ibars and COO Théophile Agresti, with Théo Vitupier and Elior Benarous
|
|
Optiverse: Revolutionizing Video Consumption with AI
Optiverse addresses a pressing challenge in today's content-rich environment: the significant time drain experienced by professionals as they engage with lengthy videos. This issue isn't limited to frontline employees, as managers and executives grapple with it. Whether it's sifting through irrelevant virtual meetings, YouTube tutorials, seminars, or other content, the cumulative effect is hundreds of lost hours per employee. Over time, this loss translates into millions of dollars wasted by companies.
Founded by Elio Assaf, Raphael Ausilio, and Mario Assaf, Optiverse's AI-driven SaaS product offers an innovative solution capable of summarizing extensive videos into concise video summaries. Their groundbreaking platform combines the strength of LLMs with an intelligent proprietary streaming engine, enabling automatic comprehension of video content, pinpointing key moments, patterns, and insights, and delivering precise information seamlessly. Positioned in a thriving market, with video streaming alone worth USD 600 billion, the growth potential is significant.
The funds obtained from VentureKick's first stage will be allocated toward market validation and product enhancement. Optiverse aims to rapidly scale up to deliver its productivity asset to the business world.
Shape Biopharmaceuticals: Redefining Immunotherapy
Shape Biopharmaceuticals focuses on developing innovative immunotherapies for chronic disease patients with high unmet treatment needs.
Shape’s immunotherapies are based on specifically engineered nanoparticles. These nanomedicines leverage the body's immune system to fight the disease. Shape combines immunobiology, chemistry, and medicine expertise to develop its medicines with state-of-the-art computer-aided drug design and engineering technologies. The company was founded by repeat biotech entrepreneurs and is managed by Dr. Arin Ghasparian (co-founder and CEO) and Dr. Armando Zuniga (co-founder and CSO), who both have longstanding leadership experience in innovative biotech companies and a track record of successfully developing novel vaccine and drug delivery technologies from scratch to clinic. Shape has built a broad international network of experts and works with leading research groups in Switzerland and abroad to achieve its goals.
Shape plans to use Venture Kick financing to help accelerate product and business development.
WasteFlow: turning waste into value with vision
Globally, 2 billion tonnes of household waste are generated yearly, yet only 13.5% is recycled. Key challenges in recycling include managing the large volume and diversity of waste and overcoming inefficiencies in facilities.
WasteFlow is led by a dedicated team including CEO Valentin Ibars, who combines technical expertise with business acumen, and COO Théophile Agresti, who manages operations. Théo Vitupier contributes his industrial knowledge to the development of WasteFlow sensors, while Elior Benarous is responsible for developing an advanced waste detection system. They are supported by long-term advisors Xavier Juredieu, offering strategic insights, and Mathieu Salzamann from EPFL's CVlab, providing technical guidance. This collaboration is further enhanced by student projects at EPFL, collectively advancing the future of recycling.
WasteFlow will utilize Venture Kick funding to strengthen relationships with existing partners and customers, enhancing collaboration and support for advanced recycling solutions.
Optiverse addresses a pressing challenge in today's content-rich environment: the significant time drain experienced by professionals as they engage with lengthy videos. This issue isn't limited to frontline employees, as managers and executives grapple with it. Whether it's sifting through irrelevant virtual meetings, YouTube tutorials, seminars, or other content, the cumulative effect is hundreds of lost hours per employee. Over time, this loss translates into millions of dollars wasted by companies.
Founded by Elio Assaf, Raphael Ausilio, and Mario Assaf, Optiverse's AI-driven SaaS product offers an innovative solution capable of summarizing extensive videos into concise video summaries. Their groundbreaking platform combines the strength of LLMs with an intelligent proprietary streaming engine, enabling automatic comprehension of video content, pinpointing key moments, patterns, and insights, and delivering precise information seamlessly. Positioned in a thriving market, with video streaming alone worth USD 600 billion, the growth potential is significant.
The funds obtained from VentureKick's first stage will be allocated toward market validation and product enhancement. Optiverse aims to rapidly scale up to deliver its productivity asset to the business world.
Shape Biopharmaceuticals: Redefining Immunotherapy
Shape Biopharmaceuticals focuses on developing innovative immunotherapies for chronic disease patients with high unmet treatment needs.
Shape’s immunotherapies are based on specifically engineered nanoparticles. These nanomedicines leverage the body's immune system to fight the disease. Shape combines immunobiology, chemistry, and medicine expertise to develop its medicines with state-of-the-art computer-aided drug design and engineering technologies. The company was founded by repeat biotech entrepreneurs and is managed by Dr. Arin Ghasparian (co-founder and CEO) and Dr. Armando Zuniga (co-founder and CSO), who both have longstanding leadership experience in innovative biotech companies and a track record of successfully developing novel vaccine and drug delivery technologies from scratch to clinic. Shape has built a broad international network of experts and works with leading research groups in Switzerland and abroad to achieve its goals.
Shape plans to use Venture Kick financing to help accelerate product and business development.
WasteFlow: turning waste into value with vision
Globally, 2 billion tonnes of household waste are generated yearly, yet only 13.5% is recycled. Key challenges in recycling include managing the large volume and diversity of waste and overcoming inefficiencies in facilities.
WasteFlow is led by a dedicated team including CEO Valentin Ibars, who combines technical expertise with business acumen, and COO Théophile Agresti, who manages operations. Théo Vitupier contributes his industrial knowledge to the development of WasteFlow sensors, while Elior Benarous is responsible for developing an advanced waste detection system. They are supported by long-term advisors Xavier Juredieu, offering strategic insights, and Mathieu Salzamann from EPFL's CVlab, providing technical guidance. This collaboration is further enhanced by student projects at EPFL, collectively advancing the future of recycling.
WasteFlow will utilize Venture Kick funding to strengthen relationships with existing partners and customers, enhancing collaboration and support for advanced recycling solutions.